Monthly Archives: January 2012

Et tu, WSJ?

First the New York Times publishes a bizarro-world opinion piece on ADHD, about which a separate post was written yesterday. Today, the Wall Street Journal publishes an article written by Shirley Wang, titled: ‘A New Target in Fighting Brain Disease: … Continue reading

Posted in Uncategorized | Tagged , , , | Leave a comment

Someone Please Wake Up Andrew Rosenthal

‘Ritalin Gone Wrong’ was the headline on the front page of the New York Times Sunday Review today, a publication which is generally seen as a source of reason, not underinformed pseudoscience. But there it was, Professor Emeritus L. Alan … Continue reading

Posted in Muddled Media, Science | Tagged , , , , | 2 Comments

Another In A Series of Unfortunate Press Releases

(from a Vanda press release, 1/26/12): “Vanda Pharmaceuticals Inc. (NASDAQ: VNDA – News) announced today that tasimelteon was shown for the first time to reset the body clock and to align it to a constant 24-hour day in patients suffering … Continue reading

Posted in BioFollies | Tagged , , , , , | Leave a comment

Cells in Negative Space

http://www.nature.com/nature/journal/vaop/ncurrent/full/nature10821.html This paper by Israel et al published in Nature on the use of induced pluripotent stem cells to generate models of familial and sporadic Alzheimer’s has received some attention. There are significant questions yet-to-be-answered about the validity of this … Continue reading

Posted in Science | Tagged | Leave a comment

Identity Crisis

At JP Morgan this year, we encountered an odd and awkward phenomenon, a Big Pharma CEO/CFO who appears to wish that they worked someplace other than in the pharmaceutical industry.  GSK‘s CFO Simon Bingemans, in his twenty minute presentation, uttered … Continue reading

Posted in Big Pharma | Tagged , , , | Leave a comment

Not With A Bang

And so we bid a not-so-fond farewell to Dimebon. It is not as if anyone–anyone?–expected the last Pfizer/Medivation clinical study for Dimebon, this one in conjunction with Aricept, to provide anything more than a postscript. Still, the announcement of that … Continue reading

Posted in Big Pharma | Tagged , , , , | 2 Comments